Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPFFR1 | Q9GZQ6 | 3/20 | 0.52 |
| ▸ | NPFFR2 | Q9Y5X5 | 3/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20340442 | 0.81 | CNR2 (0.39) | NPFFR1NPFFR2ALDH1A1SLC6A4 | |
| Hydrochloric Acid SCHEMBL7841180 | 0.81 | CYP1A2 (0.41) | NPFFR1NPFFR2CYP1A2CYP2D6CYP3A4 | |
| SCHEMBL6122826 | 0.78 | NPFFR1 (0.46) | NPFFR1NPFFR2OPRM1CYP1A2CYP2D6 | |
| SCHEMBL9749001 | 0.78 | NPFFR1 (0.46) | NPFFR1NPFFR2OPRM1CYP1A2CYP2D6 | |
| Bromide SCHEMBL7691198 | 0.77 | NPFFR1 (0.45) | NPFFR1NPFFR2OPRM1CYP1A2CYP2D6 | |
| Oxalic Acid SCHEMBL28122334 | 0.76 | NPFFR1 (0.50) | NPFFR1NPFFR2OPRM1CYP1A2CYP2D6 | |
| SCHEMBL17767843 | 0.73 | CYP2C19 (0.43) | NPFFR1NPFFR2CYP1A2CYP2D6POLB | |
| SCHEMBL3178014 | 0.72 | NPFFR1 (0.67) | NPFFR1NPFFR2OPRM1POLBCYP3A4 | |
| Hydrochloric Acid SCHEMBL6123389 | 0.72 | NPFFR1 (0.67) | NPFFR1NPFFR2OPRM1POLBCYP3A4 | |
| SCHEMBL28873836 | 0.72 | GRIN2D (0.49) | NPFFR1NPFFR2OPRM1CYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107001368-A | The 1,9 diazaspiracyclic hendecane compounds with the anti-pain activity of multiplex mode | 埃斯特韦博士实验室股份公司 | 2017-08-01 | — | — | CN | disclosed |
| US-7208604-B2 | Methods for the synthesis of alfentanil, sufentanil, and remifentanil | MALLINCKRODT INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208604-B2 | Methods for the synthesis of alfentanil, sufentanil, and remifentanil | MALLINCKRODT INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208604-B2 | Methods for the synthesis of alfentanil, sufentanil, and remifentanil | MALLINCKRODT INC. (US) | 2007-04-24 | — | — | US | disclosed |
| EP-1246801-B1 | METHODS FOR THE SYNTHESES OF ALFENTANIL, SUFENTANIL AND REMIFENTANIL | MALLINCKRODT INC (US) | 2006-09-20 | — | — | EP | disclosed |
| US-7074935-B2 | Methods for the syntheses of alfentanil, sufentanil and remifentanil | MALLINCKRODT INC. (US) | 2006-07-11 | — | — | US | disclosed |
| US-20060149071-A1 | New methods for the synthesis of alfentanil, sufentanil, and remifentanil | MALLINCKRODT, INC. | 2006-07-06 | — | — | US | disclosed |
| US-20040138461-A1 | Methods for the syntheses of alfentanil sufentanil and remifentanil | MALLINCKRODT, INC. | 2004-07-15 | — | — | US | disclosed |
| EP-1246801-A2 | METHODS FOR THE SYNTHESES OF ALFENTANIL, SUFENTANIL AND REMIFENTANIL | MALLINCKRODT INC. (US) | 2002-10-09 | — | — | EP | disclosed |
| WO-2001040184-A2 | METHODS FOR THE SYNTHESES OF ALFENTANIL, SUFENTANIL AND REMIFENTANIL | MALLINCKRODT INC. (US) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060149071-A1 | New methods for the synthesis of alfentanil, sufentanil, and remifentanil | OPRK1, OPRM1, OPRL1 | NPFFR1 285/4885NPFFR2 116/4885OPRM1 2/4885 |
| US-20040138461-A1 | Methods for the syntheses of alfentanil sufentanil and remifentanil | HNMT, OPRM1, ALKBH3 | NPFFR1 1545/4885NPFFR2 1215/4885OPRM1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.